

Phathom[®]

PHARMACEUTICALS

Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer

January 6, 2020

Martin Gilligan joins from Celgene Corporation where he led marketing, market access and business development for the Inflammation & Immunology Franchise

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Jan. 6, 2020-- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the appointment of Martin J. Gilligan as Chief Commercial Officer. Mr. Gilligan most recently was Corporate Vice President at Celgene Corporation, where he led marketing, market access and business development for Celgene's Inflammation and Immunology Franchise. He held key leadership roles in the launch and growth of OTEZLA[®] through its sale to Amgen for \$13.4 billion.

"Martin brings deep biopharmaceutical sales, marketing and market access expertise, and we're thrilled to have him join our executive team as we prepare for the potential commercialization of vonoprazan," said Terrie Curran, Chief Executive Officer of Phathom. "We expect Martin's proven commercial leadership and broad operational experience to be tremendously valuable as we continue to build out capabilities in advance of the potential launch of vonoprazan."

Mr. Gilligan is a biopharmaceutical industry veteran with more than 25 years of experience in both global and US sales and marketing roles. Prior to Celgene, he held commercial roles of increasing responsibility at Pharmacia, Johnson & Johnson and Merck. Mr. Gilligan holds a bachelor's degree from Providence College and an MBA from Rutgers University.

About Vonoprazan

Vonoprazan, is an oral small molecule potassium competitive acid blocker (P-CAB). P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of *Helicobacter pylori* (*H. pylori*) infection. The U.S. Food and Drug Administration (FDA) has designated vonoprazan as a qualified infectious disease product (QIDP) and awarded Fast Track status for the treatment of *H. pylori* infection in combination with both amoxicillin and clarithromycin and with amoxicillin alone. Phathom in-licensed the U.S., European and Canadian rights to vonoprazan from Takeda, which completed 17 Phase 3 trials for vonoprazan and received marketing approval in Japan and numerous other countries in Asia and Latin America.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company's website at www.phathompharma.com.

Forward Looking Statements

Phathom cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential regulatory approval and commercial launch of vonoprazan. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom's business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; the success of our clinical trials of vonoprazan and the results of prior clinical trials and other investigator-initiated clinical trials of vonoprazan are not necessarily predictive of our future results and the FDA and comparable foreign regulatory authorities may not accept the data from such prior trials to support approval; regulatory developments in the United States and foreign countries, including FDA and EMA developments that may be inconsistent with feedback received to date; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; and other risks described in the company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the Company's Registration Statement on Form S-1 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200106005287/en/>

Source: Phathom Pharmaceuticals, Inc.

Joe Hand
1-877-742-8466
info@phathompharma.com

Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
mikebeyer@sambrown.com

Investors:
Patti Bank
Westwicke Partners
415-513-1284
patti.bank@westwicke.com